Researchers at McMaster University have invented a stable, affordable way to store fragile vaccines for weeks at a time at temperatures up to 40C, opening the way for life-saving anti-viral vaccines to reach remote and impoverished regions of the world.
The new method combines the active ingredients in existing vaccines with a sugary gel, where they remain viable for eight weeks or more, even at elevated temperatures.
The method creates light, durable, and compact doses that would be ideal for shipping Ebola vaccine, for example, to affected regions of Africa, the researchers say. The process adds only marginal cost to preparing a vaccine and eliminates almost all the cost of transporting it – which can account for 80 per cent of the total cost of inoculation.
Combining the vaccines and the sugars – pullulan and trehalose – is almost as simple as stirring cream and sugar into coffee, the researchers say. The storage technology was created by chemical engineers at McMaster, who had already demonstrated its effectiveness in other applications, such as an edible coating that can prolong the shelf life of fruits and vegetables.
To apply the technology to vaccines, the engineers collaborated with health sciences colleagues across campus who specialize in virology and immunology. Their work is published today in the journal Scientific Reports and also appeared on the front page of the Globe and Mail newspaper.
“This, to us, is the ultimate application of this technology,” said the paper’s lead author Vincent Leung, an assistant professor of Chemical Engineering. “To imagine that something we worked on in the lab could one day be used to save people’s lives is very exciting.”
The invention is significant because it can replace the cumbersome “cold chain” – constant storage at temperatures between 2C and 8C – which is currently necessary to keep anti-viral vaccines viable. Maintaining the cold chain is a significant barrier to inoculating people in remote or poor regions of the world, where the infrastructure to refrigerate and transport vaccines smoothly may not be available.
“You can spend all kinds of money developing a vaccine, but if it is deactivated by high temperature an hour before you can give it to someone, it doesn’t matter,” says co-author Ali Ashkar, a professor of Pathology and Molecular Medicine specializing in immunology.
The cold-chain challenge is so great, the researchers say, that in some regions, vaccines must be transported by camels bearing solar-powered mini-refrigerators. There are some populations that never receive vaccines.
“If you can’t get vaccines to the places where people need them, there’s no point in having them,” says co-author Matthew Miller, an assistant professor in the Department of Biochemistry and Biomedical Sciences whose laboratory specializes viral pathogens.
Not being able to get vaccines to isolated areas makes it impossible to eradicate deadly viruses. Unchecked, such viruses can devastate local populations and reach exposed pockets in more populated countries where religious, cultural or other concerns have diminished the proportion of vaccinated individuals. Such a scenario has recently been playing out in in a measles outbreak in the US northwest and Vancouver, BC.
The new vaccine-storage method suspends the active components of a vaccine in a tiny one-dose container filled with a sugar-gel combination that dries to seal in the vaccine. Later, clinicians reconstitute the vaccine with water and administer it to patients as they ordinarily would.
“Often, complex problems have simple solutions. It just takes the right team,” says Miller. “The best research comes from merging fields, when you do something with someone else that you couldn’t do alone.”
The researchers have proven the method to be viable using two sample vaccines – influenza virus and herpes simplex virus – to inoculate and test mice by exposing them to the viruses because the immune response of mice is similar to that of humans. The materials in the storage medium are already approved by the US Food and Drug Administration, simplifying the path to commercialization.
“All the pieces are ready to go,” says co-author Carlos Filipe, chair of Chemical Engineering at McMaster. “It’s actually quite simple compared to the technology required to create a vaccine itself.”
The researchers are working with a commercial partner to get the technology to market.
Learn more: McMaster researchers invent a way to get life-saving vaccines to previously inaccessible parts of the world
The Latest on: Vaccine storage
[google_news title=”” keyword=”vaccine storage” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Vaccine storage
- Pan American Health Organization supports Cold Chain Assessment in Antigua and Barbudaon April 27, 2024 at 1:00 am
The Ministry of Health extends its gratitude to the Pan American Health Organization (PAHO) for providing a cold chain expert to conduct a comprehensive assessm ...
- Soligenix extends patent protection for its Filovirus vaccine to United Kingdom and South Africaon April 26, 2024 at 10:30 pm
Soligenix extends patent protection for its Filovirus vaccine to United Kingdom and South Africa: Princeton, New Jersey Saturday, April 27, 2024, 11:00 Hrs [IST] Soligenix, Inc, a ...
- Herb Brown, prolific Clearwater entrepreneur and philanthropist, dies at 100on April 26, 2024 at 9:52 am
Known for founding businesses in real estate, retail and the Checkers Drive-In chain, he lived “to help others in need.” ...
- Soligenix extends patent protection for its filovirus vaccine platform to the UK and South Africaon April 26, 2024 at 5:49 am
Soligenix announced it has received notice of intent to grant additional patents based on its patent application in the UK and South Africa.
- DOH calls for good maintenance of vaccine stocks amid high temperatureon April 25, 2024 at 11:38 pm
AMID the extremely high temperatures being recorded across the country, the Department of Health (DOH) called on all local health centers and rural health units ...
- Polio Eradiction Is Within Reach: Here’s What It Will Take To Get Thereon April 25, 2024 at 6:00 am
We're in the last mile in the fight to eradicate polio, but progress is fragile. A look at how UNICEF and partners are working to reach every child with polio vaccines.
- mRNA vaccine tech can be helpful in preventing deadly diseases: Reporton April 24, 2024 at 4:59 am
Unlike other vaccine technologies, mRNA enables rapid production and adaptability for evolving targets. While these vaccines require ultra-cold storage, modifyi ...
- mRNA vaccines could reduce preventable illness across multiple disease areas: GlobalDataon April 23, 2024 at 10:02 pm
However, vaccines based on this technology necessitate ultra-cold storage, and thus modifying this would make the vaccine even more desirable.
- The Moral Compass of Medicine: Exploring Ethical Dilemmason April 23, 2024 at 4:07 am
I see the desperation and it worries me." Patients asking for, say, Ozempic or Wegovy off-label prompt yet another set of ethical dilemmas, especially if there are shortages. In addition, drug costs ...
- Chris Oyakhilome: Nigerian pastor pushing malaria vaccine conspiracy theorieson April 17, 2024 at 6:55 pm
One name is repeated frequently by Pastor Oyakhilome: Bill Gates. The billionaire is one of the malaria vaccine's biggest backers, but has also been subject to vaccination conspiracy theories for ...
via Bing News